
|Articles|March 8, 2010
- September 2009
- Volume 3
- Issue 9
Studies from Around the Globe
Author(s)Onclive Team
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, integrating targeted therapies and immunotherapies for improved outcomes.
- Stereotactic radiosurgery and whole-brain radiotherapy are evolving with new systemic therapies, maintaining their importance in treatment plans.
Advertisement
Articles in this issue
over 16 years ago
By the Numbers: If the US Health Care System Had Only 100 Physiciansover 16 years ago
In the News Briefsover 16 years ago
IASLC's 13th World Conference on Lung CancerAdvertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5







































































